Influenza Clinical Trials 2023

What are the top hospitals conducting influenza research?

In the ongoing battle against influenza, several hospitals have emerged as leaders in conducting clinical trials to combat this infectious diseaset influenza, several hospitals have emerged as leaders in conducting clinical trials to combat this infectious disease. The National Institutes of Health (NIH) Clinical Center in Bethesda is at the forefront, with four active influenza trials and a total of 15 conducted over time. Notably, their first recorded influenza trial dates back to 2008, showcasing their long-standing commitment to research in combating this seasonal menace. Another institution making strides is Johnson County Clin-Trials located in Lenexa. With four ongoing influenza studies and an impressive history of 19 previous trials, they have been dedicated to finding innovative solutions since their inaugural influenza trial in 2007.

Meanwhile, Meridian Clinical Research LLC based in Omaha has been contributing significantly with three active influenza trials and a track record of successfully completing 12 such studies since commencing research on the virus back in 2004. Closer home at CTI Clinical Research Center situated in Cincinnati; they may currently be running only three investigations but had made pioneering leap forward by recording its debut experiment concerning flu cases right from2022 onwards

Finally yet importantly Insight Therapeutics LLC located at Norfolk also actively carries out three current scientific inquiries into flu cases while already having accomplished progress through five prior tests upon beginning from2013 itself.

These esteemed hospitals serve as crucial hubs for advancements not just within local communities but across the nation's collective fight against this contagious respiratory illness. By participating or administering these clinical trials patients not only gain access to potentially life-saving treatments but also become integral contributors toward future breakthroughs that can ultimately help protect millions globally

Which are the best cities for influenza clinical trials?

In the realm of influenza clinical trials, several cities emerge as key players in advancing research and treatment. Miami, Florida leads with 24 ongoing trials investigating various approaches such as SSA: bivalent BNT162b2 (dose level 1) + QIV and mRNA-1010. Omaha, Nebraska follows closely behind with 18 active studies exploring interventions like Quadrivalent influenza modRNA vaccine. Rochester, New York also boasts 18 ongoing trials evaluating options such as VAX-MOM Intervention and Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose. Lastly, San Diego, Californiaf influenza clinical trials, several cities emerge as key players in advancing research and treatment. Miami, Florida leads with 24 ongoing trials investigating various approaches such as SSA: bivalent BNT162b2 (dose level 1) + QIV and mRNA-1010. Omaha, Nebraska follows closely behind with 18 active studies exploring interventions like Quadrivalent influenza modRNA vaccine. Rochester, New York also boasts 18 ongoing trials evaluating options such as VAX-MOM Intervention and Group 1: Quadrivalent Influenza mRNA Vaccine MRT5413 low dose. Lastly, San Diego, California contributes to the field with its 17 active trials examining advances like Group 2: Quadrivalent Influenza mRNA Vaccine MRT5407 dose level 2. These cities offer fertile ground for cutting-edge research aimed at improving our understanding and management of influenza.

Which are the top treatments for influenza being explored in clinical trials?

In the realm of influenza research, several top treatments are currently under exploration in clinical trials. The first on the list is the Influenza Vaccine, which shows promise with four active trials and a total of 13 all-time influenza trials since its debut in 2008. Another contender making waves is Baloxavir, involved in two ongoing studies and listed for the first time in 2020. Equally noteworthy is Baloxavir Marboxil, also participating in two active trials and accumulating nine all-time influenza trials since its introduction in 2016. Lastly, we have High Dose Quadrivalent Inactivated Influenza Vaccine joining the ranks with two current trials underway after being listed just this year (2021). As researchers delve deeper into these innovative treatments, hope grows stronger for improved outcomes against influenza outbreaks worldwide.

What are the most recent clinical trials for influenza?

Recent clinical trials for influenza have introduced promising advancements in the field. Notably, Group i and Influenza Vaccine studies have reached Phase 4, indicating their advanced stages of testing. Additionally, Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine and Fluad investigations are progressing well in Phase 2 trials. Furthermore, Arm 2 is currently undergoing Phase 1 testing to evaluate its potential effectiveness against influenza. With these ongoing studies focused on developing effective treatments and prevention strategies for influenza, there is hope for improved management of this infectious diseaser influenza have introduced promising advancements in the field. Notably, Group i and Influenza Vaccine studies have reached Phase 4, indicating their advanced stages of testing. Additionally, Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine and Fluad investigations are progressing well in Phase 2 trials. Furthermore, Arm 2 is currently undergoing Phase 1 testing to evaluate its potential effectiveness against influenza. With these ongoing studies focused on developing effective treatments and prevention strategies for influenza, there is hope for improved management of this infectious disease in the near future.

What influenza clinical trials were recently completed?

Several recent clinical trials focused on influenza have reached completion, representing significant advancements in combating this infectious disease. In August 2022, Seqirus successfully concluded a trial evaluating the efficacy of Experimental on influenza have reached completion, representing significant advancements in combating this infectious disease. In August 2022, Seqirus successfully concluded a trial evaluating the efficacy of Experimental: aIIV-B Investigational as a single intramuscular dose. Preceding that, in July 2022, Seqirus completed a trial for aH5N6c. Other notable completed trials include FluGen Inc.'s investigation into the Cam2020 M2SR H3N2 influenza vaccine (June 2022), ModernaTX's mRNA-1073 study (May 2022), and Janssen Vaccines & Prevention B.V.'s Ad26.COV2.S research (November 2021). These studies stand testament to ongoing efforts to develop effective treatments against influenza and safeguard public health.